VivoSeq
Ophthalmology

Epiretinal Membrane

6

Pipeline Programs

1

Active Trials

4

Companies Involved

Epiretinal membrane is an early-stage landscape with 6 programs across 4 companies. The most active players are Roche, AbbVie, Novartis.

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

75/100

Attrition Rate

20/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Modality Breakdown

80%

Small molecule

8 of 10 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody220%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Trial Status

10

clinical trials

Completed6 · 60%
Terminated2 · 20%
Unknown status1 · 10%
Recruiting1 · 10%

Trial Activity

10 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)